# Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

Study · id `cardio:ct-nct03449654` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03449654](<https://clinicaltrials.gov/study/NCT03449654>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03449654

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

## Technical summary

Registry record NCT03449654. Randomized; double masking; primary purpose prevention. Start 2017-10-26 (actual); primary completion 2019-08-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT03449654, source copy `cardio:ctgov-nct03449654-2020-06-11`, retrieved 2026-10-26)
- Started: 2017-10-26 (actual) (ClinicalTrials.gov record NCT03449654, source copy `cardio:ctgov-nct03449654-2020-06-11`, retrieved 2026-10-26)
- Primary completion: 2019-08-16 (actual) (ClinicalTrials.gov record NCT03449654, source copy `cardio:ctgov-nct03449654-2020-06-11`, retrieved 2026-10-26)
- Completion: 2019-08-16 (actual) (ClinicalTrials.gov record NCT03449654, source copy `cardio:ctgov-nct03449654-2020-06-11`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT03449654, source copy `cardio:ctgov-nct03449654-2020-06-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03449654-2020-06-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes
- Acronym: LIRAFLAME
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Liraglutide
- Intervention (Drug): Placebo (for liraglutide)
- Lead sponsor: Steno Diabetes Center Copenhagen
- Lead sponsor class: OTHER
- Collaborator: Copenhagen University Hospital, Rigshospitalet
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Steno Diabetes Center Copenhagen (`cardio:org-steno-diabetes-center-copenhagen`)
- Registry lists this organization as a collaborator: Copenhagen University Hospital, Rigshospitalet (`cardio:org-copenhagen-university-hospital-rigshospitalet`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Liraglutide on Arterial Inflammation Assessed as \[18F\]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (`cardio:pubmed-34187185`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial (`cardio:pubmed-34518158`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1d4126bf830354f3301d126b644b115c623ebb64ec20e0a013df828967975aa2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
